|0.7125 0.013 (1.79%)||08-04 15:58|
|Targets||6-month :||0.85||1-year :||0.87|
|Resists||First :||0.72||Second :||0.74|
|Supports||First :||0.69||Second :||0.58|
|MAs||MA(5) :||0||MA(20) :||0|
|MA(100) :||0||MA(250) :||0|
|MACD||MACD :||0||Signal :||0|
|%K %D||K(14,3) :||0||D(3) :||0|
|52-week||High :||0.74||Low :||0.69|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENOB ] has closed Bollinger Bands are 0% narrower than normal.
|If tomorrow:||Open lower||Open higher|
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.
Mon, 17 Jul 2023
3 Doomed Biotech Stocks Destined for Disaster - InvestorPlace
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||0 (M)|
|Held by Insiders||0 (%)|
|Held by Institutions||0 (%)|
|Shares Short||0 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||0 %|
|Return on Equity (ttm)||0 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||0 (M)|
|Price to Book value||0|
|Price to Sales||0|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|